Search for
IHC Comprehensive panel for diagnosis
Cancer
Report in 192Hrs
At Home
No Fasting Required
Details
Tumor immunohistochemistry panels.
₹8,880₹12,686
30% OFF
IHC Comprehensive Panel for Diagnosis - Complete Medical Guide
- Section 1: Why is it done?
- Test Overview: Immunohistochemistry (IHC) is a molecular pathology technique that uses antibodies to detect specific antigens in tissue samples. The comprehensive panel involves staining multiple markers simultaneously on a single tissue specimen to identify cellular characteristics, protein expressions, and disease-specific markers.
- Primary Indications for Ordering: Classification and diagnosis of malignant tumors (carcinomas, lymphomas, sarcomas); determination of tumor origin in cases of metastatic cancer; prognostic assessment of known malignancies; prediction of treatment response and therapy selection; differentiation between benign and malignant lesions; identification of specific tumor subtypes; detection of biomarkers for targeted therapy eligibility
- Typical Timing and Circumstances: Performed on tissue samples obtained through biopsy, surgical excision, or resection specimens; typically ordered when morphology alone is insufficient for diagnosis; performed immediately after initial histopathological review; essential in oncology workup for newly diagnosed cancers; may be repeated if initial panel is inconclusive or for re-evaluation of treatment response
- Common Clinical Scenarios: Suspected breast cancer requiring HER2, ER, PR assessment; lymphoma classification; sarcoma differentiation; diagnostic uncertainty on H&E staining; metastatic tumor of unknown primary; tumor staging and grading; predicting chemotherapy or immunotherapy response
- Section 2: Normal Range
- Reference Interpretation System: IHC results are typically reported as negative (−) or positive (+), with positive results graded on intensity and distribution: 0 (negative); 1+ (weak); 2+ (moderate); 3+ (strong). Some panels use percentage distribution (0-100% of cells staining positive).
- Normal Values by Common Markers: Estrogen Receptor (ER): Negative or <5% positive nuclei = normal; HER2: 0 or 1+ = normal; Progesterone Receptor (PR): Negative or <5% positive nuclei = normal; KI-67 (proliferation index): <20% = low proliferation (normal in benign tissue); CD20, CD3, CD4, CD8 (lymphoid markers): Expected distribution varies by tissue type; PD-L1: Negative in most normal tissues; Cytokeratins: Present in epithelial tissues (normal finding); Vimentin: Present in mesenchymal cells (normal finding)
- Units of Measurement: Percentage of positive cells (0-100%); Staining intensity (0, 1+, 2+, 3+); H-score (calculated from intensity × percentage, range 0-300); Qualitative descriptors (negative, positive, equivocal)
- Interpretation Guidelines: Negative Result: Absence of specific antigen expression; typically associated with normal tissue or benign lesions; may indicate absence of specific tumor characteristics. Positive Result: Presence of antigen expression; indicates abnormal cellular characteristics or tumor-specific markers; intensity and distribution pattern provide clinical significance. Borderline/Equivocal: Results requiring expert interpretation; may necessitate repeat testing or additional confirmatory studies; clinical correlation with morphology essential.
- Interpretation of Normal vs Abnormal: Normal IHC patterns support benign diagnoses or normal tissue findings; unexpected positive markers may indicate malignancy, metaplasia, or inflammation; absent markers in suspicious lesions may exclude specific diagnoses; concordance of multiple markers strengthens diagnostic confidence
- Section 3: Interpretation
- Detailed Result Interpretation: Negative (0/−): Complete absence of staining; indicates lack of specific antigen; favors benign diagnosis or excludes particular tumor types. Weakly Positive (1+): Faint staining in <10% of cells; borderline significance; requires clinical correlation; may indicate early malignant change. Moderately Positive (2+): Intermediate staining intensity in 10-50% of cells; significant finding suggesting specific disease; requires interpretation with morphology. Strongly Positive (3+): Intense staining in >50% of cells; highly significant for malignancy or specific tumor type; strongly supports specific diagnosis
- Clinical Significance of Different Patterns: Membrane Staining: Characteristic of growth factor receptors (HER2); indicates functional significance. Nuclear Staining: Seen with hormone receptors (ER, PR); indicates transcriptional activity. Cytoplasmic Staining: Associated with viral infections or specific protein types; may indicate altered cellular function. Diffuse vs Focal Pattern: Diffuse staining suggests widespread expression; focal pattern may indicate clonality or specific cellular populations
- Factors Affecting IHC Interpretation: Tissue quality and fixation: Poor fixation or prolonged storage may reduce antigen detection; ischemia time affects staining reliability. Antibody specificity: Cross-reactivity may produce false positives; multiple antibody clones strengthen interpretation. Background staining: Non-specific staining may complicate results; internal controls essential for validation. Tumor heterogeneity: Different cellular populations may show variable staining; sampling variation can affect results. Host immune response: Inflammatory infiltrate may confound interpretation; lymphocytic staining must be distinguished from neoplastic staining
- Clinical Significance of Result Patterns: ER+/PR+/HER2−: Hormone-responsive breast cancer; responsive to endocrine therapy. ER−/PR−/HER2+: HER2-driven breast cancer; candidate for trastuzumab or other anti-HER2 therapy. Triple-Negative (ER−/PR−/HER2−): Aggressive breast cancer; chemotherapy-dependent; candidate for immunotherapy. CD20+ B-cell lymphoma: Responsive to rituximab-based therapy. CD3+ T-cell lymphoma: Different therapeutic approach; often chemotherapy-based. High PD-L1 expression: Potential candidate for checkpoint inhibitor immunotherapy. High KI-67: Indicates aggressive behavior; higher proliferation rate; worse prognosis
- Section 4: Associated Organs
- Primary Organ Systems Involved: Integumentary system (skin cancers, melanoma); Lymphoid system (lymphomas, leukemias); Reproductive system (breast cancer, ovarian cancer, prostate cancer); Gastrointestinal system (gastric cancer, colorectal cancer, esophageal cancer); Respiratory system (lung cancer, mesothelioma); Urinary system (bladder cancer, renal cancer); Nervous system (brain tumors, meningiomas); Endocrine system (thyroid cancer, adrenal tumors)
- Diseases and Conditions Diagnosed: Carcinomas (adenocarcinoma, squamous cell carcinoma, transitional cell carcinoma); Non-Hodgkin lymphomas (DLBCL, follicular lymphoma, Burkitt lymphoma); Hodgkin lymphoma; Sarcomas (osteosarcoma, Ewing sarcoma, synovial sarcoma); Melanoma and skin malignancies; Mesothelioma; Germ cell tumors; Neuroendocrine tumors; Metastatic tumors of unknown primary
- Associated Abnormal Findings: Increased proliferation index (KI-67 elevation); Loss of normal differentiation markers; Acquisition of growth factor receptors; Immune evasion markers (PD-L1 upregulation); Altered adhesion molecule expression; Increased vascular markers (angiogenesis); Epithelial-to-mesenchymal transition markers; Stem cell marker expression
- Prognostic and Risk Implications: Hormone receptor positive status: Generally better prognosis; lower recurrence risk; responsive to endocrine therapy. HER2 amplification: Higher risk of aggressive behavior; benefit from targeted therapy; risk of cardiac toxicity with treatment. High proliferation markers: Associated with aggressive tumors; faster disease progression; poorer prognosis if untreated. Expression of immune checkpoints (PD-L1): May predict immunotherapy response; prognostic significance varies by malignancy type. Loss of differentiation: Associated with higher grade; increased malignant potential; worse prognosis
- Potential Complications Related to Abnormal Results: Rapid disease progression in aggressive tumors; Organ dysfunction from tumor burden; Metastatic spread if untreated; Treatment toxicity from targeted therapies; Secondary malignancies from chemotherapy or radiation; Immune-related adverse events from immunotherapy; Organ-specific complications (cardiac toxicity, pulmonary toxicity, hepatic toxicity); Psychological impact of malignancy diagnosis
- Section 5: Follow-up Tests
- Complementary Pathology Studies: Fluorescence In Situ Hybridization (FISH): For HER2 gene amplification confirmation; gene copy number analysis. Flow Cytometry: For lymphoid malignancy phenotyping; assessment of immunophenotypic abnormalities. Cytogenetic studies: Chromosomal abnormalities; detection of specific translocations (t(9;22), t(15;17)). Next-Generation Sequencing (NGS): Comprehensive mutation profiling; identification of targetable mutations; assessment of tumor burden. In Situ Hybridization (ISH): EBER for EBV detection; HPV detection in squamous lesions
- Additional Diagnostic Testing: Repeat IHC panel: If initial results equivocal or contradictory; with alternative antibody clones for confirmation. Tissue microarray analysis: For standardized comparison across multiple specimens. Immunofluorescence studies: Multiplex analysis of multiple antigens simultaneously. Special stains: PAS for carbohydrates; Gram stain for bacteria; AFB stain for mycobacteria; Trichrome for muscle disorders
- Imaging and Clinical Follow-up Tests: CT or MRI imaging: Staging and assessment of tumor burden; detection of metastatic disease. PET-CT scan: Metabolic activity assessment; detection of occult metastases. Bone scan: For skeletal involvement assessment. Chest X-ray: Baseline imaging; monitoring for pulmonary metastases. Laboratory studies: Tumor markers (PSA, CEA, AFP, beta-hCG); baseline blood work before therapy
- Monitoring During Treatment: Serial tumor marker measurements: Monthly during active treatment; quarterly during remission; varies by malignancy type. Repeat imaging: Every 3-4 months during treatment; every 6 months during surveillance phase. Re-biopsy in selected cases: Treatment-naive disease reassessment; progression evaluation; at physician discretion. Tissue-based molecular profiling: Assessing treatment response; identifying acquired resistance mutations
- Long-term Surveillance and Monitoring Frequency: Year 1 post-treatment: Every 1-3 months clinical assessment. Years 2-5: Every 3-6 months imaging and clinical evaluation. After 5 years: Annual surveillance for most malignancies; some high-risk tumors require longer monitoring. Symptom-driven evaluation: Any concerning symptoms warrant immediate investigation. Ongoing laboratory monitoring: Liver and kidney function assessment; cardiac evaluation if applicable; surveillance for secondary malignancies
- Section 6: Fasting Required?
- Fasting Requirement: NO - Fasting is NOT required for IHC testing
- Rationale: IHC is performed on tissue samples obtained via biopsy or surgical resection, not blood samples. Fasting status does not affect tissue specimen quality or staining results. The test analyzes fixed, processed tissue sections on microscope slides, not serum or plasma components.
- Specimen Collection Requirements: Tissue must be properly fixed in neutral buffered formalin within 1-2 hours of collection; specimens must be labeled with patient identifiers and anatomical site; tissue should be adequate in size (minimum 3-5mm); representative areas of lesion must be included; avoidance of cauterized or crushed tissue margins is essential; proper storage in formalin-filled containers required
- Pre-biopsy Instructions for Patients: Fasting is NOT necessary unless biopsy procedure requires sedation or anesthesia; if general anesthesia planned, standard fasting guidelines apply (typically 6-8 hours NPO); patient should continue regular medications unless specifically instructed otherwise; avoid aspirin and NSAIDs for 5-7 days prior if possible (anticoagulation concerns); arrange for transport if sedation planned; inform physician of bleeding disorders or anticoagulation therapy
- Medications to Avoid: Anticoagulants (warfarin, direct oral anticoagulants): Discuss with physician; may need to hold prior to biopsy. Antiplatelet agents (aspirin, clopidogrel): Consider discontinuation 5-7 days before procedure. NSAIDs: May increase bleeding risk; avoid for 1 week prior to biopsy. Herbal supplements with anticoagulant properties (ginkgo, garlic): Discontinue 1-2 weeks before procedure. Note: Do NOT discontinue prescribed medications without physician consultation; restart medications as directed after procedure
- General Patient Preparation: Wear loose, comfortable clothing to facilitate biopsy site access; remove jewelry and metal objects; arrange for transportation if sedation planned; inform healthcare provider of allergies (local anesthetics, betadine, latex); provide complete medical history and medication list; allow adequate time (typically 1-2 hours) for procedure and recovery; expect recovery time ranging from 30 minutes to 2 hours depending on sedation used; post-biopsy site care instructions typically include keeping area clean and dry, avoiding vigorous activity for 24 hours
- Timing for Results: Standard turnaround: 5-10 business days from tissue receipt; Complex cases or extensive panels: 10-15 business days; Expedited processing: 2-3 business days (additional charges may apply); Urgent cases: Same-day or next-day availability in some institutions; Results provided to ordering physician who discusses findings with patient
How our test process works!
